GSK (LON:GSK) Given “Underweight” Rating at JPMorgan Chase & Co.

GSK (LON:GSK)‘s stock had its “underweight” rating reissued by analysts at JPMorgan Chase & Co. in a report released on Tuesday, Digital Look reports.

GSK has been the topic of a number of other research reports. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a GBX 1,950 ($24.66) target price on shares of GSK in a report on Friday. Citigroup reissued a “buy” rating and issued a GBX 2,100 ($26.56) price objective on shares of GSK in a research note on Monday, June 24th. Shore Capital restated a “buy” rating on shares of GSK in a research note on Thursday, June 27th. Jefferies Financial Group reiterated a “buy” rating and set a GBX 2,100 ($26.56) price target on shares of GSK in a research note on Thursday, June 27th. Finally, Barclays reissued an “equal weight” rating and set a GBX 1,725 ($21.82) price target on shares of GSK in a report on Tuesday, May 7th. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, GSK currently has a consensus rating of “Moderate Buy” and an average target price of GBX 1,791.25 ($22.66).

GSK Stock Performance

Shares of GSK stock opened at GBX 1,506.50 ($19.06) on Tuesday. The stock’s 50-day moving average price is GBX 1,685.84 and its 200 day moving average price is GBX 1,632.29. The company has a quick ratio of 0.73, a current ratio of 0.87 and a debt-to-equity ratio of 134.34. The stock has a market capitalization of £61.47 billion, a PE ratio of 1,382.11, a price-to-earnings-growth ratio of 1.19 and a beta of 0.27. GSK has a 52-week low of GBX 1,302.60 ($16.48) and a 52-week high of GBX 1,823.50 ($23.06).

Insider Buying and Selling

In related news, insider Wendy Becker bought 446 shares of the stock in a transaction that occurred on Thursday, June 20th. The stock was purchased at an average cost of GBX 1,614 ($20.41) per share, for a total transaction of £7,198.44 ($9,105.03). 1.60% of the stock is currently owned by company insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.